To further validate the results, we examined the expression levels in 11 normal prostate tissues and 14 prostate cancer tissues with real-time PCR. All of these lncRNAs except LINC00969, were expressed significantly higher in prostate cancer samples compared with normal prostate tissues, which were consistent with the TCGA and microarray results. Then, the expression levels of ten lncRNAs were validated in the noncancerous prostatic cells WPMY-1 and four human prostate cancer cell lines by qRT-PCR. It turned out that most of the ten lncRNAs were up-regulated in prostate cancer cell lines and showed a similar expression pattern in patient samples. The CCK8 assay showed that knockdown of LINC01138 or SUZ12P1 markedly suppressed cell viability in LNCaP cells.